Profound MedicalTSX:PRN +7.28%68 Market Cap is C$380.09 Mil as of Jul. 07, 2026. GuruFocus rates TSX:PRN with a GF Score™ of 68/100 and a GF Value™ of C$20.37 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 868 Medical Devices & Instruments companies, Profound Medical ranks better than 60.25% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Profound Medical's share price for the quarter that ended in Mar. 2026 was C$8.9. Profound Medical's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 36.34 Mil. Therefore, Profound Medical's market cap for the quarter that ended in Mar. 2026 was C$323.41 Mil.
Profound Medical's quarterly market cap
increased
from Sep. 2025 (C$205.32 Mil) to Dec. 2025 (C$390.89 Mil) but then
declined
from Dec. 2025 (C$390.89 Mil) to Mar. 2026 (C$323.41 Mil).
Profound Medical's annual market cap
increased
from Dec. 2023 (C$237.22 Mil) to Dec. 2024 (C$324.43 Mil) and
increased
from Dec. 2024 (C$324.43 Mil) to Dec. 2025 (C$390.89 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Profound Medical's Enterprise Value for Today is C$319.28 Mil.
Profound Medical (TSX:PRN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Profound Medical Market Cap Related Terms
Profound Medical Market Cap Historical Data
* Premium members only.
The historical data trend for Profound Medical's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Profound Medical's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profound Medical Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's Market Cap distribution charts can be found below:
* The bar in red indicates where Profound Medical's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Profound Medical's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profound Medical (TSX:PRN) has a Market Cap of C$380.09 Mil as of Jul. 07, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Profound Medical and its competitors. According to the industry distribution chart, Profound Medical ranks #345 out of 868 companies in the Medical Devices & Instruments industry, placing it in the top 39.7%.
Is Profound Medical's Market Cap too high?
Profound Medical's current Market Cap is C$380.09 Mil. Based on the distribution chart, Profound Medical ranks #345 out of 868 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Profound Medical has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's Market Cap compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Profound Medical ranks #345 out of 868 companies for Market Cap. This puts Profound Medical in the upper half of its industry. The industry median Market Cap is 121.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 121.35, based on 868 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Profound Medical and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 121.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profound Medical's current Market Cap is C$380.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (TSX:PRN) is currently considered Possible Value Trap. The stock's GF Value™ is C$20.37, compared to a current price of C$10.46 — trading 48.6% below its estimated fair value. The current Market Cap is C$380.09 Mil. Profound Medical's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Profound Medical (TSX:PRN), the current Market Cap is C$380.09 Mil as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profound Medical (TSX:PRN) Overvalued in 2026?
Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued.
The current stock price of C$10.46 is trading 48.6% below its estimated GF Value™ of C$20.37.
GuruFocus considers Profound Medical to be Possible Value Trap.
Key valuation signals for TSX:PRN:
Market Cap: C$380.09 Mil
GF Value™: C$20.37 vs. price of C$10.46 (48.6% below fair value)
No single metric tells the full story. See the TSX:PRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
68GF Score
Get the complete analysis for TSX:PRN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:PRN has been successfully added to your 
